NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ammonium chloride 0.9% in normal saline is an injectable electrolyte solution administered intravenously. It is used to treat metabolic alkalosis and hypochloremic states by restoring chloride and hydrogen ion balance. The mechanism involves providing chloride ions that promote renal excretion of bicarbonate and correction of acid-base abnormalities.
PRE_LAUNCH
Pre-launch stage indicates limited current commercial activity; career opportunities will emerge post-approval in commercial operations, market access, and field teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers on this Pfizer product during pre-launch phase are limited but will expand significantly upon approval, focusing on market access, hospital/clinical adoption, and field execution. This is a foundational opportunity for professionals seeking experience in specialty injectables and hospital-based product launches.
Brand ManagerMarket Access Manager
Worked on AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.